Yuri Hirayama

1.1k total citations
26 papers, 807 citations indexed

About

Yuri Hirayama is a scholar working on Neurology, Cellular and Molecular Neuroscience and Physiology. According to data from OpenAlex, Yuri Hirayama has authored 26 papers receiving a total of 807 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Neurology, 7 papers in Cellular and Molecular Neuroscience and 7 papers in Physiology. Recurrent topics in Yuri Hirayama's work include Neuroinflammation and Neurodegeneration Mechanisms (9 papers), Adenosine and Purinergic Signaling (7 papers) and Neuroscience and Neuropharmacology Research (5 papers). Yuri Hirayama is often cited by papers focused on Neuroinflammation and Neurodegeneration Mechanisms (9 papers), Adenosine and Purinergic Signaling (7 papers) and Neuroscience and Neuropharmacology Research (5 papers). Yuri Hirayama collaborates with scholars based in Japan, United Kingdom and United States. Yuri Hirayama's co-authors include Schuichi Koizumi, Yosuke M. Morizawa, Eiji Shigetomi, Junichi Nabekura, Shinsuke Shibata, Hirohide Takebayashi, Yang Sui, Kōichi Sato, Fumikazu Okajima and Nobuhiko Ohno and has published in prestigious journals such as Nature Communications, Journal of Neuroscience and SHILAP Revista de lepidopterología.

In The Last Decade

Yuri Hirayama

25 papers receiving 805 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yuri Hirayama Japan 11 394 235 175 117 113 26 807
Yosuke M. Morizawa Japan 9 357 0.9× 167 0.7× 175 1.0× 118 1.0× 89 0.8× 11 660
Mingshu Mo China 14 386 1.0× 199 0.8× 173 1.0× 153 1.3× 58 0.5× 31 751
Stefka Gyoneva United States 14 607 1.5× 355 1.5× 169 1.0× 209 1.8× 76 0.7× 20 1.0k
Elisa M. York Canada 12 626 1.6× 234 1.0× 159 0.9× 270 2.3× 111 1.0× 17 918
Dylan A. Galloway Canada 11 334 0.8× 294 1.3× 82 0.5× 173 1.5× 102 0.9× 11 700
Przemyslaw Swiatkowski United States 8 343 0.9× 116 0.5× 204 1.2× 111 0.9× 63 0.6× 9 568
Fabia Filipello Italy 13 596 1.5× 257 1.1× 163 0.9× 341 2.9× 150 1.3× 16 1.0k
Barbara Orsolits Hungary 7 490 1.2× 168 0.7× 121 0.7× 212 1.8× 108 1.0× 10 698
Christina A. Welsh United States 9 659 1.7× 245 1.0× 296 1.7× 289 2.5× 168 1.5× 9 1.0k
Sabrina Etteri Italy 5 199 0.5× 179 0.8× 135 0.8× 136 1.2× 163 1.4× 5 781

Countries citing papers authored by Yuri Hirayama

Since Specialization
Citations

This map shows the geographic impact of Yuri Hirayama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuri Hirayama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuri Hirayama more than expected).

Fields of papers citing papers by Yuri Hirayama

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuri Hirayama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuri Hirayama. The network helps show where Yuri Hirayama may publish in the future.

Co-authorship network of co-authors of Yuri Hirayama

This figure shows the co-authorship network connecting the top 25 collaborators of Yuri Hirayama. A scholar is included among the top collaborators of Yuri Hirayama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuri Hirayama. Yuri Hirayama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hirayama, Yuri, Maie Shahid, Helene M. Finney, et al.. (2025). Comparison of outcomes for Draf IIB vs Draf III in endoscopic frontal sinus surgery: a comprehensive systematic review and meta-analysis. Rhinology Journal. 0(0). 0–0. 1 indexed citations
2.
3.
Mowforth, Oliver, K.M. John Chan, Yuri Hirayama, et al.. (2024). Degenerative Cervical Myelopathy Awareness in Primary Care: UK National Cross-Sectional Survey of General Practitioners. JMIR Formative Research. 8. e58802–e58802. 2 indexed citations
4.
Hirayama, Yuri, et al.. (2024). Preconditioning-Induced Facilitation of Lactate Release from Astrocytes Is Essential for Brain Ischemic Tolerance. eNeuro. 11(4). ENEURO.0494–23.2024. 3 indexed citations
5.
Sakamoto, Shinichi, Xue Zhao, Tomohiro Tamura, et al.. (2022). Targeting L-type amino acid transporter 1 in urological malignancy: Current status and future perspective. Journal of Pharmacological Sciences. 150(4). 251–258. 5 indexed citations
6.
Hirayama, Yuri, Naohiko Anzai, Hiroyuki Kinouchi, & Schuichi Koizumi. (2022). P2X7 Receptors in Astrocytes: A Switch for Ischemic Tolerance. Molecules. 27(12). 3655–3655. 9 indexed citations
7.
Koizumi, Schuichi & Yuri Hirayama. (2022). Ischemic Tolerance Induced by Glial Cells. Neurochemical Research. 47(9). 2522–2528. 4 indexed citations
8.
Mowforth, Oliver, et al.. (2022). Tremor as a symptom of degenerative cervical myelopathy: a systematic review. British Journal of Neurosurgery. 36(3). 340–345. 5 indexed citations
9.
Hashimoto, Hirofumi, et al.. (2022). Effects of a novel hepatitis B anti-viral drug E-CFCP in renal organic acid transporters. Journal of Pharmacological Sciences. 150(4). 201–203.
10.
Hirayama, Yuri, Oliver Mowforth, Benjamin M. Davies, & Mark Kotter. (2021). Determinants of quality of life in degenerative cervical myelopathy: a systematic review. British Journal of Neurosurgery. 37(1). 71–81. 17 indexed citations
11.
Hirayama, Yuri, et al.. (2021). Protein kinase C activation upregulates human L-type amino acid transporter 2 function. The Journal of Physiological Sciences. 71(1). 11–11. 3 indexed citations
12.
Fukuuchi, Tomoko, Kiyoko Kaneko, Yuri Hirayama, et al.. (2021). Effects of islatravir (4′-ethynyl-2-fluoro-2′-deoxyadenosine or EFdA) on renal tubular cells and islatravir's interactions with organic anion transporters. Journal of Pharmacological Sciences. 146(2). 82–87. 3 indexed citations
13.
Tanaka, Masayoshi, Eiji Shigetomi, Bijay Parajuli, et al.. (2021). Adenosine A2B receptor down‐regulates metabotropic glutamate receptor 5 in astrocytes during postnatal development. Glia. 69(11). 2546–2558. 10 indexed citations
14.
Kinoshita, Manao, Yuri Hirayama, Kayoko Fujishita, et al.. (2018). Anti-Depressant Fluoxetine Reveals its Therapeutic Effect Via Astrocytes. EBioMedicine. 32. 72–83. 92 indexed citations
15.
Koizumi, Schuichi, Yuri Hirayama, & Yosuke M. Morizawa. (2018). New roles of reactive astrocytes in the brain; an organizer of cerebral ischemia. Neurochemistry International. 119. 107–114. 56 indexed citations
16.
Morizawa, Yosuke M., Yuri Hirayama, Nobuhiko Ohno, et al.. (2017). Reactive astrocytes function as phagocytes after brain ischemia via ABCA1-mediated pathway. Nature Communications. 8(1). 28–28. 317 indexed citations
17.
Hirayama, Yuri & Schuichi Koizumi. (2017). Astrocytes and ischemic tolerance. Neuroscience Research. 126. 53–59. 26 indexed citations
18.
Hirayama, Yuri, Yuri Ikeda‐Matsuo, Shoji Notomi, et al.. (2015). Astrocyte-Mediated Ischemic Tolerance. Journal of Neuroscience. 35(9). 3794–3805. 96 indexed citations
19.
Hirayama, Yuri, et al.. (2013). Transplantated Mesenchymal Stem Cells Derived from Embryonic Stem Cells Promote Muscle Regeneration and Accelerate Functional Recovery of Injured Skeletal Muscle. SHILAP Revista de lepidopterología. 2(4). 295–306. 23 indexed citations
20.
Ikeda‐Matsuo, Yuri, et al.. (2010). Microsomal prostaglandin E synthase‐1 contributes to ischaemic excitotoxicity through prostaglandin E2 EP3 receptors. British Journal of Pharmacology. 160(4). 847–859. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yosuke M. Morizawa Breakdown of academic impact, for papers by Mingshu Mo Breakdown of academic impact, for papers by Stefka Gyoneva Breakdown of academic impact, for papers by Elisa M. York Breakdown of academic impact, for papers by Dylan A. Galloway Breakdown of academic impact, for papers by Przemyslaw Swiatkowski Breakdown of academic impact, for papers by Fabia Filipello Breakdown of academic impact, for papers by Barbara Orsolits Breakdown of academic impact, for papers by Christina A. Welsh Breakdown of academic impact, for papers by Sabrina Etteri
Rankless by CCL
2026